Published in Thromb Haemost on May 01, 1999
The practical management of claudication. BMJ (2000) 1.12
Renal artery stenosis-when to screen, what to stent? Curr Atheroscler Rep (2014) 0.92
Peripheral arterial disease: Epidemiology, natural history, diagnosis and treatment. Int J Angiol (2007) 0.87
Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences? Naunyn Schmiedebergs Arch Pharmacol (2006) 0.83
Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered. Int J Nephrol Renovasc Dis (2010) 0.78
Peripheral arterial disease. BMJ Clin Evid (2011) 0.77
Peripheral arterial disease. BMJ Clin Evid (2007) 0.75
Antithrombotic treatment for peripheral arterial disease. Heart (2006) 0.75
Empirical evidence of design-related bias in studies of diagnostic tests. JAMA (1999) 12.96
The long-term clinical course of acute deep venous thrombosis. Ann Intern Med (1996) 6.87
Compression ultrasonography for diagnostic management of patients with clinically suspected deep vein thrombosis: prospective cohort study. BMJ (1998) 6.07
Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med (1992) 5.48
Travel and risk of venous thrombosis. Lancet (2000) 5.23
Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet (1995) 5.10
Once versus thrice daily gentamicin in patients with serious infections. Lancet (1993) 4.92
Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet (1992) 4.15
Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med (1996) 4.10
Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med (2003) 3.94
Subcutaneous heparin compared with continuous intravenous heparin administration in the initial treatment of deep vein thrombosis. A meta-analysis. Ann Intern Med (1992) 3.74
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost (2007) 3.66
Accuracy of clinical assessment of deep-vein thrombosis. Lancet (1995) 3.45
Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med (1996) 3.42
Upper-extremity deep vein thrombosis. Risk factors, diagnosis, and complications. Arch Intern Med (1997) 3.35
Diagnostic utility of ultrasonography of leg veins in patients suspected of having pulmonary embolism. Ann Intern Med (1997) 3.26
Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators. N Engl J Med (2001) 3.07
Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med (1990) 2.82
Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints. Lancet (1999) 2.77
Detection of deep-vein thrombosis by real-time B-mode ultrasonography. N Engl J Med (1989) 2.73
Endotoxaemia: an early predictor of septicaemia in febrile patients. Lancet (1988) 2.67
Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. Lancet (2000) 2.49
A comparison of real-time compression ultrasonography with impedance plethysmography for the diagnosis of deep-vein thrombosis in symptomatic outpatients. N Engl J Med (1993) 2.39
Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol (2000) 2.35
Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood (1990) 2.33
Activation of coagulation system during air travel: a crossover study. Lancet (2006) 2.32
Mortality in hereditary antithrombin-III deficiency--1830 to 1989. Lancet (1991) 2.31
Extensive screening for occult malignant disease in idiopathic venous thromboembolism: a prospective randomized clinical trial. J Thromb Haemost (2004) 2.28
Meta-analysis: the final answer, or even more confusion? Lancet (1996) 2.24
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost (2013) 2.24
Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet (1997) 2.20
Prevention of deep vein thrombosis after hip replacement--comparison between two low-molecular heparins, tinzaparin and enoxaparin. Thromb Haemost (1999) 2.18
Limitations of compression ultrasound for the detection of symptomless postoperative deep vein thrombosis. Lancet (1994) 2.18
Non-pharmaceutical measures for prevention of post-thrombotic syndrome. Cochrane Database Syst Rev (2004) 2.16
High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost (2000) 2.15
Plasma levels of matrix metalloproteinase-9: a possible diagnostic marker of successful endovascular aneurysm repair. Eur J Vasc Endovasc Surg (2011) 2.14
A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score. J Thromb Haemost (2010) 2.08
Use of preventive measures for air travel-related venous thrombosis in professionals who attend medical conferences. J Thromb Haemost (2006) 2.06
[Atherosclerosis partly due to local vasculitis]. Ned Tijdschr Geneeskd (1994) 2.05
Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study. J Thromb Haemost (2014) 2.03
[Optimal treatment with oral anticoagulants]. Ned Tijdschr Geneeskd (1996) 2.03
Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med (1999) 2.00
Deep-vein thrombosis. Lancet (1999) 1.98
Psychological aspects and coping in haemophilic patients: a case-control study. Haemophilia (2003) 1.98
Triage of patients for short term observation after elective coronary angioplasty. Heart (2000) 1.97
Venous thromboembolism prophylaxis: do trial results enable clinicians and patients to evaluate whether the benefits justify the risk? Proceedings of an Ad Hoc Working Group Meeting. J Thromb Haemost (2013) 1.97
Application of treatment thresholds to diagnostic-test evaluation: an alternative to the comparison of areas under receiver operating characteristic curves. Med Decis Making (1997) 1.96
Compression ultrasonography of the leg veins in patients with clinically suspected pulmonary embolism: is a more extensive assessment of compressibility useful? Thromb Haemost (2000) 1.95
Incidence of cancer after a first episode of idiopathic venous thromboembolism treated with 3 months or 1 year of oral anticoagulation. J Thromb Haemost (2003) 1.95
Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. Arch Intern Med (1999) 1.95
Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. J Thromb Haemost (2009) 1.95
Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev (2004) 1.84
Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med (1999) 1.81
Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis. Circulation (1992) 1.78
Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med (1990) 1.76
Association of idiopathic venous thromboembolism with single point-mutation at Arg506 of factor V. Lancet (1994) 1.76
A simple clinical model for the diagnosis of deep-vein thrombosis combined with impedance plethysmography: potential for an improvement in the diagnostic process. J Intern Med (1998) 1.76
The risk of recurrent venous thromboembolism in patients with an Arg506-->Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med (1997) 1.75